Open Label, Single Arm, Phase I/II Study of CADI-05 in Patients With Advanced Stage III or Stage IV Melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2009
At a glance
- Drugs Cadi 05 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Cadila Pharmaceuticals
- 12 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Jun 2008 New trial record.